ARCT · CIK 1768224
What Arcturus Therapeutics Holdings Inc. told the SEC could break it.
Arcturus' register centers on dependence at both ends of its business. Its revenue is overwhelmingly tied to a single partner — about 80% came from CSL Seqirus in 2025, largely non-recurring milestone and license payments it may not receive again — while it has recognized no product-sales revenue since inception and carries a $514.6 million accumulated deficit, leaving it reliant on collaborations and equity financing. On the manufacturing side it buys certain raw materials from single-source suppliers with no qualified backups, and sources components globally (including the PRC, Japan and Europe), so proposed U.S. tariffs on foreign-sourced materials could raise its production costs or force costlier alternative sourcing.
4 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Sole-source dependency
- Single-source raw materials with no qualified backup suppliershigh
Arcturus purchases certain raw materials from single-source suppliers and lacks qualified backup suppliers, so a supplier disruption or bankruptcy could prevent it from manufacturing product candidates in sufficient quantities or on acceptable terms.
“the lack of qualified backup suppliers for any raw materials that are currently purchased from a single source supplier”
SEC filing →As of 2026
Customer concentration
- Revenue overwhelmingly from CSL Seqirus collaboration (~80%)medium
Arcturus generated ~80% of total revenue from CSL in 2025, largely from non-recurring milestone and license payments under its CSL Seqirus collaboration; it may not receive future milestone payments, creating extreme revenue concentration.
“In 2025 we recognized a significant portion of our revenue from non-recurring milestone payments and license revenue under our collaboration agreement with CSL Seqirus. We may not receive any future milestone payments from CSL Seqirus.”
SEC filing →As of 2026
Liquidity & debt
- No product-sales revenue and large accumulated deficitmedium
Arcturus has recognized no revenue from product sales since inception and has a $514.6M accumulated deficit, having funded operations through collaborations and equity (ATM); only KOSTAIVE is approved (abroad), so it remains dependent on financing.
“We have not recognized any revenue from product sales since our inception. As of December 31, 2025, we had an accumulated deficit of $514.6 million.”
SEC filing →As of 2026
Regulatory & policy
- Proposed tariffs on PRC and other foreign-sourced raw materialsmedium
Arcturus sources product-candidate components and raw materials globally (PRC, Japan, Austria, Germany, UK); proposed U.S. tariffs (especially on PRC) could raise production costs or force costlier alternative sourcing that delays clinical trials and manufacturing.
“The current U.S. presidential administration has proposed the implementation of a number of tariffs, including tariffs on products and materials from PRC, which could increase our production costs.”
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
CSL Seqirus (CSL Limited)
“In 2025 we recognized a significant portion of our revenue from non-recurring milestone payments and license revenue under our collaboration agreement with CSL Seqirus. We may not receive any future milestone payments from CSL Seqirus.”
Cited →Meiji Seika Pharma, Ltd.
“Commercial sales of KOSTAIVE began in October 2024 in Japan by Meiji Seika Pharma, Ltd. (“Meiji”), CSL Seqirus' exclusive partner in Japan, marking the first commercial sales of an Arcturus-developed product.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch